![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Departments of Medicinal Chemistry (M.T.) and Oncology (F.V.) Aventis Pharmaceuticals, Vitry-Sur-Seine, France; and Department of Drug Safety Evaluation, Aventis Pharmaceuticals, Bridgewater, New Jersey (J.K., X.-L.C., H.W., J.J., H.C., J.I., W.R., D.R.)
Abstract
Many drugs inhibit the human ether-a-go-go-related gene (HERG) cardiac K+ channel. This leads to action potential prolongation on the cellular level, a prolongation of the QT interval on the electrocardiogram, and sometimes cardiac arrhythmia. To date, no activators of this channel have been reported. Here, we describe the in vitro electrophysiological effects of (3R,4R)-4-[3-(6-methoxyquinolin-4-yl)-3-oxo-propyl]-1-[3-(2,3,5-trifluoro-phenyl)-prop-2-ynyl]-piperidine-3-carboxylic acid (RPR260243), a novel activator of HERG. Using patch-clamp electrophysiology, we found that RPR260243 dramatically slowed current deactivation when applied to cells stably expressing HERG. The effects of RPR260243 on HERG channel deactivation were temperature- and voltage-dependent and occurred over the concentration range of 1 to 30 µM. RPR260243-modified HERG currents were inhibited by dofetilide (IC50 = 58 nM). RPR260243 had little effect on HERG current amplitude and no significant effects on steady-state activation parameters or on channel inactivation processes. RPR260243 displayed no activator-like effects on other voltage-dependent ion channels, including the closely related erg3 K+ channel. RPR260243 enhanced the delayed rectifier current in guinea pig myocytes but, when administered alone, had little effect on action potential parameters in these cells. However, RPR260243 completely reversed the action potential-prolonging effects of dofetilide in this preparation. Using the Langendorff heart method, we found that 5 µM RPR260243 increased T-wave amplitude, prolonged the PR interval, and shortened the QT interval. We believe RPR260243 represents the first known HERG channel activator and that the drug works primarily by inhibiting channel closure, leading to a persistent HERG channel current upon repolarization. Compounds like RPR260243 will be useful for studying the physiological role of HERG and may one day find use in treating cardiac disease.
Address correspondence to: Dr. David Rampe, Aventis Pharmaceuticals, Inc., Route 202–206, Building JR2-2236, Bridgewater, NJ 08807-0800. E-mail: david.rampe{at}aventis.com
This article has been cited by other articles:
|
|
 |
|
  Z. Gao, Q. Xiong, H. Sun, and M. Li Desensitization of Chemical Activation by Auxiliary Subunits: CONVERGENCE OF MOLECULAR DETERMINANTS CRITICAL FOR AUGMENTING KCNQ1 POTASSIUM CHANNELS J. Biol. Chem., August 15, 2008; 283(33): 22649 - 22658. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. G. Diness, Y.-H. Yeh, X. Y. Qi, D. Chartier, Y. Tsuji, R. S. Hansen, S.-P. Olesen, M. Grunnet, and S. Nattel Antiarrhythmic properties of a rapid delayed-rectifier current activator in rabbit models of acquired long QT syndrome Cardiovasc Res, July 1, 2008; 79(1): 61 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Xu, M. Recanatini, M. Roberti, and G.-N. Tseng Probing the Binding Sites and Mechanisms of Action of Two Human Ether-a-go-go-Related Gene Channel Activators, 1,3-bis-(2-Hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) and 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD307243) Mol. Pharmacol., June 1, 2008; 73(6): 1709 - 1721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Perry and M. C. Sanguinetti A Single Amino Acid Difference between Ether-a-go-go- Related Gene Channel Subtypes Determines Differential Sensitivity to a Small Molecule Activator Mol. Pharmacol., April 1, 2008; 73(4): 1044 - 1051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Fernandez, J. Sargent, F. B. Sachse, and M. C. Sanguinetti Structural Basis for Ether-a-go-go-Related Gene K+ Channel Subtype-Dependent Activation by Niflumic Acid Mol. Pharmacol., April 1, 2008; 73(4): 1159 - 1167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Gordon, I. M. Lozinskaya, Z. Lin, S. F. Semus, F. E. Blaney, R. N. Willette, and X. Xu 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic Acid (PD-307243) Causes Instantaneous Current through Human Ether-a-go-go-Related Gene Potassium Channels Mol. Pharmacol., March 1, 2008; 73(3): 639 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Perry, F. B. Sachse, and M. C. Sanguinetti Structural basis of action for a human ether-a-go-go-related gene 1 potassium channel activator PNAS, August 21, 2007; 104(34): 13827 - 13832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Hansen, S.-P. Olesen, and M. Grunnet Pharmacological Activation of Rapid Delayed Rectifier Potassium Current Suppresses Bradycardia-Induced Triggered Activity in the Isolated Guinea Pig Heart J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 996 - 1002. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Y. M. Yeung and I. A. Greenwood Pharmacological and biophysical isolation of K+ currents encoded by ether-a-go-go-related genes in murine hepatic portal vein smooth muscle cells Am J Physiol Cell Physiol, January 1, 2007; 292(1): C468 - C476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zeng, I. M. Lozinskaya, Z. Lin, R. N. Willette, D. P. Brooks, and X. Xu Mallotoxin Is a Novel Human Ether-a-go-go-Related Gene (hERG) Potassium Channel Activator J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 957 - 962. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Hansen, T. G. Diness, T. Christ, E. Wettwer, U. Ravens, S.-P. Olesen, and M. Grunnet Biophysical Characterization of the New Human Ether-A-Go-Go-Related Gene Channel Opener NS3623 [N-(4-Bromo-2-(1H-tetrazol-5-yl)-phenyl)-N'-(3'-trifluoromethylphenyl)urea] Mol. Pharmacol., October 1, 2006; 70(4): 1319 - 1329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Casis, S.-P. Olesen, and M. C. Sanguinetti Mechanism of Action of a Novel Human ether-a-go-go-Related Gene Channel Activator Mol. Pharmacol., February 1, 2006; 69(2): 658 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Hansen, T. G. Diness, T. Christ, J. Demnitz, U. Ravens, S.-P. Olesen, and M. Grunnet Activation of Human ether-a-go-go-Related Gene Potassium Channels by the Diphenylurea 1,3-Bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) Mol. Pharmacol., January 1, 2006; 69(1): 266 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhou, C. E. Augelli-Szafran, J. A. Bradley, X. Chen, B. J. Koci, W. A. Volberg, Z. Sun, and J. S. Cordes Novel Potent Human Ether-a-Go-Go-Related Gene (hERG) Potassium Channel Enhancers and Their in Vitro Antiarrhythmic Activity Mol. Pharmacol., September 1, 2005; 68(3): 876 - 884. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
